A Phase 1/2 interventional study of ABBV-6628 and SYFOVRE in Geographic Atrophy and Age-Related Macular Degeneration, sponsored by AbbVie. Recruiting at 5 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.
Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 60th largest by planned enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2025, is one of 17 in phase 1/2, reaches primary completion later than 39 of the 44 other live ones, and was the 115th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
University of Utah · Sites in United States
Ages 65–90
Cellio Therapeutics Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 65 · Phase 3 20
First in 2000; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is close to the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 98 across the 107 interventional studies, 138 across the 24 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 131 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 2 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
12 of the studies in Geographic Atrophy with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06769048Boehringer IngelheimA Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | 2026-12-22 |
| NCT07747662University of Wisconsin, MadisonAdaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study | 2027-02 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 131 studies in Geographic Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD. The purpose of this study is to assess the adverse events and how intravitreal ABBV-6628 moves through the body of adult participants with secondary to age-related macular degeneration
ABBV-6628 is an investigational monoclonal antibody fragment being developed for the treatment of geographic atrophy (GA) secondary to (AMD) age-related macular degeneration. Participants in the Stage 1 part will be placed in 1 of 4 groups, called treatment arms. Participants in Stage 2 will be placed into 1 of 2 groups. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis GA secondary to age-related macular degeneration will be enrolled. Around 66 participants will be enrolled in the study at approximately 27 sites across the US.
Participants in Stage 1 will be given ABBV-6628 as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection) with dose escalation. Participants in Stage 2 will receive ABBV-6628 or SYFOVRE, an approved treatment for geographic atrophy, administered as per the FDA-approved label. The treatment duration is approximately 22 months and 3 months of follow-up.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Stage 1 and Stage 2
-Diagnosed with Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in the study eye.
Stage 1
Stage 2
Exclusion Criteria:
Stage 1 and Stage 2
Participants will receive a single dose of ABBV-6628 in Cohort 1 on day 1.
Drug: ABBV-6628
Participants will receive a single dose of ABBV-6628 in Cohort 2 on day 1.
Drug: ABBV-6628
Participants will receive a single dose of ABBV-6628 in Cohort 3 on day 1.
Drug: ABBV-6628
Participants will receive ABBV-6628 in Cohort 4 on day 1 and month 2.
Drug: ABBV-6628
Participants will receive ABBV-6628 for approximately 22 months followed by 3 months of follow-up.
Drug: ABBV-6628
Participants will receive SYFOVRE for approximately 22 months followed by 3 months of follow-up.
Drug: SYFOVRE
Intravitreal injection
Intravitreal injection
Number of Participants Experiencing Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 25 months
Number of Participants with Abnormal Change in Physical Examinations
Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, gastrointestinal, and neurological systems will be assessed.
Time frame: Up to approximately 25 months
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.
Time frame: Up to approximately 25 months
Change From Baseline in Electrocardiograms (ECGs)
12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).
Time frame: Up to approximately 25 months
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.
Time frame: Up to approximately 25 months
Change from baseline in Best Corrected Visual Acuity (BCVA)
BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS) (normal luminance and low luminance visual acuity)
Time frame: Up to approximately 25 months
Change in Slit lamp biomicroscopy assessment
Changes in Slit lamp biomicroscopy assessed by the physician will be assessed.
Time frame: Up to approximately 25 months
Change in Intraocular pressure (IOP)
Measured by using Goldmann applanation tonometry (GAT) or hand-held tonometer
Time frame: Up to approximately 25 months
Change in Lens examination assessment
Changes in Lens examination assessed by the physician will be assessed.
Time frame: Up to approximately 25 months
Change in Ophthalmoscopy assessment
Changes in Ophthalmoscopy assessed by the physician will be assessed.
Time frame: Up to approximately 25 months
Change in fundus autofluorescence (FAF) imaging assessed by Investigator
Fundus autofluorescence (FAF) imaging assessed by Investigator
Time frame: Up to approximately 25 months
Change in Retinal evaluation
Measured by color fundus photography (CFP) imaging assessed by Investigator
Time frame: Up to approximately 25 months
Change in spectral domain optical coherence tomography (SD-OCT)
Spectral domain optical coherence tomography (SD-OCT)
Time frame: Up to approximately 25 months
Change in Fluorescein angiography (FA) assessed by Investigator.
Fluorescein angiography (FA) assessed by Investigator
Time frame: Up to approximately 25 months
Change in choroidal neovascularization (CNV) assessed by Investigator.
Choroidal Neovascularization (CNV) assessed by Investigator.
Time frame: Up to approximately 25 months
Percentage of Participants with Clinically Significant Post-treatment Administration Assessment (study eye only) Findings as Assessed by the Investigator
Post-treatment Administration Assessment (study eye only)
Time frame: Up to approximately 25 months
Maximum Serum Concentration (Cmax) of ABBV-6628
Cmax of ABBV-6628
Time frame: Up to approximately 25 months
Time to Cmax (Tmax) of ABBV-6628
Tmax of ABBV-6628
Time frame: Up to approximately 25 months
Area Under the Concentration-Time Curve From zero to the last measurable Timepoint (AUC0-Tlast) of ABBV-6628
AUC0-Tlast of ABBV-6628
Time frame: Up to approximately 25 months
Stage 2-Trough serum concentration immediately before next dose (Ctrough) of ABBV-6628
Ctrough of ABBV-6628
Time frame: Up to approximately 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Oct 2029, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan